![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2007 The Authors. Journal compilation © 2007 The Physiological Society Attenuated fever in rats during late pregnancy is linked to suppressed interleukin-6 production after localized inflammation with turpentine 1Douglas Hospital Research Centre, Department of Psychiatry, McGill University, 6875 LaSalle Boulevard, Verdun, Quebec, Canada H4H 1R3 2National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK Corresponding author G. N. Luheshi: Douglas Hospital Research Centre, Department of Psychiatry, McGill University, 6875 LaSalle Boulevard, Verdun, Quebec, Canada H4H 1R3. Email: giamal.luheshi/at/mcgill.ca Received March 19, 2007; Accepted May 31, 2007. This article has been cited by other articles in PMC.Abstract An attenuated fever response to pathogens during late pregnancy is a phenomenon that has been described in several mammalian species, and although mechanisms are not completely understood, decreased prostaglandin E2 (PGE2) synthesis has been implicated. Upstream of PGE2, there is evidence to suggest that anti-inflammatory cytokines such as interleukin-1 receptor antagonist (IL-1ra) could play a significant role. In the present study we addressed the role of pro-inflammatory cytokines during late pregnancy, specifically interleukin-6 (IL-6), an important circulating mediator in fever. Turpentine oil (TURP), a very potent pyrogen and activator of IL-6, was injected into the hind-limb muscle of rats at the 18th day of pregnancy (GD 18) or in non-pregnant (NP) age-matched female controls. As expected, TURP injection induced a highly significant fever in the NP animals, which peaked 11 h post-injection and lasted for over 24 h. This was accompanied by a significant rise in circulating IL-6 levels, which correlated with changes in PGE2 synthesizing enzymes expression in the hypothalamus. In complete contrast, TURP-induced fever was totally absent in GD 18 animals whose body temperature did not deviate from basal values. The lack of response was additionally reflected by the absence of change in IL-6 concentration and by the significant attenuation of PGE2 synthesizing enzymes expression, which correlated with the suppressed expression of SOCS3, a hypothalamic marker of IL-6 activity. Contrary to the changes in circulating IL-6 levels at GD 18, IL-1ra was induced to levels comparable to those of NP females, suggesting that the influence of this anti-inflammatory cytokine on the fever response to TURP is at best minimal. These data further confirm the importance of IL-6 in fever generation and provide evidence that it may be a key component of the attenuated fever response in late pregnancy. Fever is a hallmark response to injury or infection with a well-established adaptive value (Kluger & Rothenburg, 1979; Kluger, 1991; Roth, 2006); its induction, duration, magnitude and relapse are tightly regulated by the balance between the members of a family of endogenous mediators known as cytokines that can act as pro-inflammatory/pyrogenic (interleukin (IL)-1β; tumour necrosis factor α (TNFα) and IL-6) or anti-inflammatory/cryogenic intermediaries (the endogenous IL-1 receptor antagonist (IL-1ra) and IL-10 among others) (Kluger, 1991; Leon, 2002; Roth, 2006). In the central nervous system, pyrogenic cytokines induce prostaglandin E2 (PGE2) synthesis, the ultimate step in fever induction (Ivanov et al. 2002; Ivanov & Romanovsky, 2004; Rummel et al. 2006) by the transcriptional induction of cyclooxygenase-2 (COX-2) and microsomal PGE synthase-1 (mPGES-1), the rate-limiting enzymes of this pathway (Lacroix & Rivest, 1998; Ivanov & Romanovsky, 2004; Matsumura & Kobayashi, 2004). Disruption of this tightly controlled process could result in an abnormal fever response, such as that observed during late pregnancy where an attenuated response to exogenous pathogens has been documented in several mammalian species. In these studies experimental animals including mice, rats, sheep and guinea pigs (Kasting et al. 1978; Martin et al. 1995), exhibited a reduction in the fever response to infusion of either the viral mimic polyinosinic: polycytidylic acid (poly I:C) (Cooper et al. 1988), endotoxin lipopolysaccharide (LPS) (Kasting et al. 1978; Zeisberger et al. 1981; Martin et al. 1995) or endogenous pyrogens such as IL-1β (Simrose & Fewell, 1995) and PGEs (Stobie-Hayes & Fewell, 1996; Eliason & Fewell, 1997). Several studies have linked this to a reduction in central PGE2 synthesis (Imai-Matsumura et al. 2002), probably as a result of blunted hypothalamic COX-2 induction (Imai-Matsumura et al. 2002; Mouihate et al. 2002). Recently, the involvement of central nitric oxide synthase suppressing LPS-induced fever at late pregnancy has been suggested (Begg et al. 2007). What remains uncertain is the nature of the peripheral signals responsible for the reduced COX-2 expression and, ultimately, the fever response. We have recently reported (Ashdown et al. 2006b) that higher than normal circulating levels of IL-1ra in LPS-treated pregnant rats at the later stages of pregnancy, could be partly responsible for these effects. In support of these findings we further demonstrated a causal link between increased levels of circulating IL-1ra and hypothalamic COX-2 induction. Unlike IL-1ra, however, no consistent differences were reported on the ability of animals at late stages of pregnancy to synthesize pro-inflammatory/pyrogenic cytokines in response to LPS. In these animals the LPS-induced production of IL-1β and IL-6 were reported to be reduced when compared with virgin females (Fofie et al. 2005), but not when compared with earlier stages of pregnancy or in lactating dams, whose febrile response is higher in magnitude than dams in late pregnancy (Mouihate et al. 2005). It has been also suggested that near-term pregnancy suppression of fever may stem from the inability to mount an appropriate/full response to circulating pro-inflammatory cytokines (Chen et al. 1999). This, however, has not been supported by the finding that intracellular signalling pathways triggered by LPS/IL-1β or LPS-induced IL-6 to induce COX-2 remained intact with no differences reported between pregnant dams at early and late stages of pregnancy (Mouihate et al. 2005; Harre et al. 2006). Particularly surprising about these findings is in regard to IL-6, which we and others have demonstrated to be a critical component of the fever response (Kozak et al. 1997, 2006; Cartmell et al. 2000; Rummel et al. 2006). The circulating levels of IL-6 increase dramatically following a systemic inflammatory challenge and correlate significantly with the fever response. During late pregnancy the levels of IL-6 appear to remain unchanged when compared with GD 15 controls (Harre et al. 2006). This observation argues against the importance of this cytokine in the regulation of the fever response. One possibility for this anomaly may lie in the type of stimulus being used. For instance, the majority of studies investigating this aspect (Cooper et al. 1988; Fofie & Fewell, 2003; Fofie et al. 2005; Mouihate et al. 2005; Harre et al. 2006), including ours (Ashdown et al. 2006b), have used a generalized systemic challenge namely LPS or poly I:C. These immunogens tend to act by triggering a robust immune response, which involves the targeting of multiple organs/systems to induce cytokine' release (Givalois et al. 1994; Cartmell et al. 2001; Turrin et al. 2001). Such an overwhelming response may be a factor masking any intricate changes that may occur in the levels of circulating pyrogens such as IL-6. We have previously described a model of localized inflammation, namely the intramuscular (i.m.) injection of turpentine oil (TURP), that induces fever by the activation of febrile effectors in a more defined serial fashion (Luheshi et al. 1997; Leon, 2002). The mode of action of this potent pyrogen involves the production of localized necrotic damage (Wusteman et al. 1990), which results in the sequential induction of TNFα and IL-1β at the site of injury (Zheng et al. 1995; Luheshi et al. 1997). The locally increased cytokines, particularly IL-1β, induce IL-6 synthesis and release into the circulation (Luheshi et al. 1997; Turnbull et al. 2003). A particular advantage of this approach is that it facilitates the study of IL-6 without the influence of other circulating cytokines. Given this property, we sought to characterize the particular role of IL-6 in fever generation in late-pregnant rats (gestational day 18 (GD 18)) by measuring the changes in its levels in the circulation and how they correlate with the fever response, and by investigating changes in brain mechanisms regulating the fever response to this important circulating pyrogen. Methods Adult female Sprague–Dawley rats (Charles River, Saint Constant, Quebec, Canada) were used in all experiments; two kinds of animals were employed: randomly cycling non-pregnant (NP) females (250–300 g) and primiparous pregnant females at gestational day 18 (GD 18; 250–340 g). All the individual experimental procedures for this study were approved by the Animal Care Committee of McGill University. Care throughout the duration of the experiment was provided according to the Canadian Council of Animal Care guidelines. Animals were housed individually in a controlled environment at an ambient temperature of 21 ± 2°C; they had free access to food and water and were handled for at least 7 days prior to experimentation. Observations were carried out in a 12 h:12 h light–dark cycle (lights on from 08:00 to 20:00 h). In all studies, animals received a single intramuscular (i.m.) injection of 100 μl of purified turpentine oil (TURP) (Riedel-deHaën, Sleeze, Germany) or 100 μl of sterile physiological saline (SAL) into the gastrocnemius muscle of the left hind limb. Animals were killed (see details below) 11 h after either treatment. Measurement of body temperature Changes in core body temperature were measured using remote radio-biotelemetry (Data Sciences, St Paul, MN, USA) as previously described (Sachot et al. 2004). Briefly, anaesthetized animals (i.m.; 50 mg kg−1 ketamine hydrochloride, 5 mg kg−1 xylazine hydrochloride, 0.5 mg kg−1 acepromazine maleate; 1 μl (g body weight)−1) were implanted intraperitoneally (i.p.) with pre-calibrated temperature-sensitive radio transmitters (TA10TA-F40, Data Sciences). The level of anaesthesia was assessed by the withdrawal reflex to a toe pinch. Pregnant females were implanted on GD 7 and allowed to recover until GD 18. Transmitter output frequency (Hz) was monitored, at 10 min intervals, by an antenna mounted in a receiver board, situated beneath the cage of each animal. The output data from each transmitter were transformed into degrees centigrade by Dataquest software (Data Sciences). On the day of the experiment, NP and GD 18 females were separated into SAL or TURP groups (n = 5–7 per group). Injections were administered between 08:00 and 09:00 h and the changes in core body temperatures monitored up to 11 h post-treatment. Body temperature data were analysed by calculating the area under the temperature-versus-time curve (AUC or fever index) for each animal; mean AUC per group was used for statistical analysis. Plasma cytokine measurements Plasma concentrations of IL-6, IL-1β and IL-1ra were determined from animals killed at the peak of the febrile response, 11 h after TURP injection, in order to measure the maximum humoral responses to the TURP challenge. Blood was collected from animals deeply anaesthetized with a lethal dose of pentobarbital sodium (i.p.; 60 mg (kg body weight)−1) via cardiac puncture (n = 5–7 per group) using sterile heparinized syringes and placed into sterile tubes. Samples were then centrifuged (5300 g, 15 min at 4°C), aliquoted and stored at −80°C until assays were performed. Sandwich enzyme-linked immunosorbent assays (ELISA) for IL-6, IL-1β and IL-1ra (NIBSC, Potters Bar, UK) were performed as previously described (Rees et al. 1999), except that plasma samples and secondary antibodies (NIBSC) were diluted in a buffer containing 0.5 m NaCl, 2.5 mm NaH2PO4, 7.5 mm Na2HPO4, 0.1% Tween 20, 1% ovalbumin and 1: 100 normal sheep serum (Sigma-Aldrich, St Louis, MO, USA). Intra-assay and inter-assay variations were below 10%. The detection limit for IL-6 and IL-1β was 40 pg ml−1, and 78 pg ml−1 for IL-1ra. All samples were assayed in duplicate. Hypothalamus dissection Killed animals designated for plasma collection were perfused with sterile physiological saline (prepared in DEPC-treated H2O); brains were dissected, frozen on dry ice and stored at −80°C until used. Hypothalami were microdissected from frozen tissue and divided into right and left hemispheric portions; the left hemisphere was used for RNA extraction and the right for protein extraction. RNA extraction and RT–PCR in the hypothalamus In order to asses the changes in transcription of SOCS3, IL-1β, COX-2 and mPGES-1 genes in the hypothalamus, reverse transcription (RT), followed by PCR were performed as previously reported (Rummel et al. 2006). Briefly, total RNA was extracted by disaggregating tissues in 1 ml of TRIzol (Invitrogen, Burlington, ON, Canada). Total RNA was isolated according to the manufacturer's protocol and the air-dried RNA pellet dissolved in 50 μl of DEPC-treated water. One microgram of total RNA was transcribed into DNA. PCR reactions were performed for COX-2, mPGES-1, SOCS3, IL-1β and β-actin using 1.8 μl of cDNA and 6 pmol of specific primers (Alpha DNA, Montreal, QC, Canada) for COX-2 (forward: 5′-TGATAGGAGAGACGATCAAGA-3′; reverse: 5′-ATGGTAGAGGGCTTTCAACT-3′), mPGES-1 (forward: 5′-TTTCTGCTCTGCAGCACACT-3″; reverse: 5′-CATGGAGAAACAGGTGAACT-3′), SOCS3 (forward: 5′-CCAGCGCCACTTCTTCAC-3′; reverse: 5′-GTGGAGCATCATACTGGTCC-3′), IL-1β (forward: 5′-CCCAAGCACCTTCTTTTCCTTCATCTT-3′, reverse: 5′-CAGGGTGGGTGTGCCGTCTTTC-3′) and β-actin (forward: 5′-GCCGTCTTCCCCTCCATCGTG-3′; reverse: 5′-TACGACCAGAGGCATACAGGGACAAC-3′) using a Gene Amp PCR system 9700 Thermocycler (Applied Biosystems, Foster City, CA, USA). The following parameters were used: (1) 5 min at 94°C (all primer pairs); (2) 30 s at 94°C, 30 s at 60°C (for SOCS3, IL-1β and β-actin) or 57°C (for mPGES-1 and COX-2), followed by 45 s at 72°C for 20, 28, 34, 36 or 40 cycles (for β-actin, COX-2, mPGES-1, IL-1β and SOCS3, respectively); and (3) 72°C for 10 min (for all primer pairs). PCR products were separated by gel electrophoresis (1.5% agarose) and band densities were obtained using GeneTool image analysis software (Syngen, Frederick, MD, USA). Each cDNA data were expressed as a ratio of β-actin optical density and then relative to measurements obtained from the SAL group of NP females ((gene X/β-actin mRNA)/(mean of gene X/β-actin from SAL-NP group)) in order to pool data from different gels. Initial PCR experiments using total RNA were performed for each pair of primers to ensure that products did not result from genomic DNA amplification. Additionally, the linear phase of PCR amplification of cDNA was determined by performing RT–PCR on a sample from each treatment group for an increasing number of cycles (20–50 cycles). Protein extraction and hypothalamic COX-2 Western blot analysis The right side of the hypothalamus was disaggregated in lysis buffer (50 mm Tris-HCl, 2 mm EDTA and 1% Nonidet) that included a protease inhibitor cocktail for general use (Sigma-Aldrich). Protein content was quantified using Bradford's reagent (Sigma-Aldrich) following manufacturer's instructions, aliquoted and frozen at −80°C until used. On the day of the analytical procedure the protein was mixed (1: 1) with Laemmli running buffer (Bio-Rad Laboratories, Mississauga, ON, Canada) mixed with β-mercaptoethanol (50 μl of β-mercaptoethanol per millilitre of Laemmli buffer; Sigma-Aldrich) and incubated at 95°C for 5 min. This (50 μg) was then loaded into pre-cast acrylamide gels (4–20% Tris-glycine gel, Invitrogen) and electrophoresed for 2 h at 125 V. The protein was then transferred (overnight at 15 V) to nitrocellulose membranes (Hybond ECL, Amersham Biosciences Corp., Piscataway, NJ, USA) using Xcell II Blot Module (Invitrogen), following the manufacturer's instructions for liquid transference. For immunodetection, membranes were blocked with 1 × Tris-buffer saline (TBS), 10% non-fat dry milk (Bio-Rad Laboratories) and 0.1% Tween 20 for 2 h at room temperature. Membranes were then incubated overnight (at 4°C) with a mixture of antibodies raised against murine COX-2 (1: 1000; Cayman Chemical, Hornby, ON, Canada) and actin (1: 10 000, Sigma-Aldrich) diluted in 1 × TBS, 5% milk and 0.1% Tween 20. After, antibody excess was washed (1 × for 15 min and 4 × for 5 min) with 1 × TBS, 0.1% Tween 20, membranes were incubated with a detection antibody (1: 2000; donkey anti-rabbit IgG-HRP, Santa Cruz Biotechnology, Santa Cruz, CA, USA; diluted in 1 × TBS, 1% milk and 0.1% Tween 20) for 1 h at ambient temperature. After a similar series of washing steps, the membranes were incubated with ECL Western blotting detection reagents (0.125 ml cm−2; Amersham Biosciences Corp.) for 1 min and then exposed to a chemoluminescence sensitive film (Hyperfilm ECL, Invitrogen) for 1–5 min. Films were digitized and optical density was determined using GeneTool image analysis software (Syngen, Frederick, MD, USA). Two bands were detected, one at approximately 42 kDa corresponding to actin and another at ~72 kDa corresponding to COX-2. Levels of COX-2 expression were expressed as a ratio of the β-actin signal and then, as for PCR data, as relative amounts of the measurements obtained for the SAL-NP females in order to pool data from different membranes. Data analysis All data are presented as mean values ±s.e.m. and were analysed using StatView software (version 4.57, Abacus Concepts Inc., Berkeley, CA, USA). One-way ANOVA was used to analyse the data from the temperature, ELISA, PCR and Western blot studies. In cases where comparisons using ANOVA were significant, Newman–Keuls multiple comparisons test was performed. Correlations between parameters were analysed and expressed as fitness to linear curve (r2); statistical significance was determined by ANOVA. In all cases, P values less than 0.05 were deemed statistically significant. Results TURP-induced fever is abolished in late pregnancy Basal core-body temperature (Tc) was generally lower in pregnant animals compared with NP females (Fig. 1
Circulating levels of cytokines: dampened IL-6 induction is associated with the absence of fever response At the peak of the fever response, 11 h after TURP injection, NP females showed a 5.4-fold increase in the concentration of IL-6, from 27.4 ± 9.2 pg ml−1 in the SAL group (n = 5) up to 146 ± 29 pg ml−1 in the TURP-injected animals (n = 7; one-way ANOVA: F3,19= 6.42, P < 0.01; Newman–Keuls test versus SAL-injected NP females: P = 0.0012; Fig. 2A
NP females showed a significant correlation between plasma IL-6 concentration and Tc (r2= 0.74, P = 0.0003; top panel Fig. 2B Circulating IL-1β and IL-1ra levels were also assayed. IL-1β levels were found to be below detection limits of the assay in all animals tested (NP and GD 18 females; data not shown). TURP-injected groups had a similar rise in IL-1ra concentrations (one-way ANOVA: F3,17= 9.86, P = 0.0005; Newman–Keuls test: P > 0.05), from 406 ± 49 pg ml−1 and 500 ± 55 pg ml−1 under the SAL treatment up to 3151 ± 668 pg ml−1 and 2067 ± 386 pg ml−1 11 h after TURP injection in NP and GD 18 animals, respectively (Newman–Keuls test SAL- versus TURP-injected NP females: P < 0.01; and SAL- versus TURP-injected GD 18 dams: P < 0.05; Fig. 2C Changes in circulating IL-6 levels correlate with hypothalamic SOCS3 mRNA expression To further confirm that circulating IL-6 was acting on the hypothalamus, SOCS3 mRNA was measured in the same animals used for cytokine determination. SOCS3, which is induced by the IL-6-activated intracellular signalling pathway (Lebel et al. 2000), is part of a negative feedback mechanism that limits the pro-inflammatory actions of this cytokine (Croker et al. 2003). In NP females, 11 h after TURP injection, SOCS3 mRNA was induced ~1.8-fold compared with SAL-injected females (one-way ANOVA: F3,19= 8.79, P = 0.0007; Newman–Keuls test versus SAL-injected NP group: P < 0.001; Fig. 3A
Fever pathways in the hypothalamus: evidence of blunted prostaglandin synthesis and reduced induction of IL-1β Expression of COX-2 was determined by RT-PCR; 11 h after TURP injection, hypothalamic COX-2 mRNA was significantly induced (1.9-fold) in NP females compared with SAL-injected ones (one-way ANOVA: F3,19= 11.39, P = 0.0002; Newman–Keuls test: P < 0.001; Fig. 4A
In order to confirm the RT-PCR data, COX-2 expression was assayed by Western blot. NP females had 3-fold more COX-2 levels after TURP injection (one-way ANOVA: F3,18= 4.6, P = 0.015; Newman–Keuls test versus SAL-injected NP group: P < 0.01; Fig. 4B Similar to the changes in COX-2, mPGES-1 mRNA levels were significantly up-regulated in NP (2.15-fold; one-way ANOVA: F3,19= 11.8, P = 0.0001; Newman–Keuls test versus SAL-NP females: P < 0.0001) and GD 18 females (1.7-fold; Newman–Keuls test versus SAL-GD 18 dams: P < 0.05; Fig. 5
In NP females, expression levels of COX-2 (measured as mRNA or as protein) and mPGES-1 correlated significantly with circulating IL-6 levels (Table 1). SOCS3 mRNA levels correlated with the expression levels of both enzymes (Table 1). In late-pregnant rats no correlation was found between IL-6 and COX-2 or mPGES-1 (Table 1). However, similar to cycling females, SOCS3 mRNA levels correlated with those of COX-2 and mPGES-1 (Table 1).
Although IL-1β was not detected in the circulation, it has been proposed that centrally it plays a significant role in TURP-induced fever (Luheshi et al. 1997). Therefore we decided to measure the expression of its mRNA levels within the hypothalamus. In TURP-injected NP females IL-1β mRNA was significantly induced (2.4-fold, one-way ANOVA: F3,19= 13.26, P = 0.0001; Newman–Keuls test versus SAL-injected NP group: P < 0.0001; Fig. 6A
Discussion In the present study we demonstrated that a TURP challenge, which would normally induce a highly significant and prolonged fever response in non-pregnant rats, was almost totally ineffective during late pregnancy (Fig. 1 Our current observations demonstrating drastically reduced levels of IL-6 (and consequently hypothalamic SOCS3 mRNA) and COX-2 after TURP injection during late pregnancy, provide a possible mechanism underlying the reported reduction in PGE2 levels in the brain, the ultimate step in fever generation (Fewell et al. 2002; Imai-Matsumura et al. 2002; Mouihate et al. 2002). These findings are similar to those reported previously in IL-6 ‘knock out’ mice, which were shown to be resistant to TURP-induced fever (Kozak et al. 1997), and exhibit significantly attenuated COX-2 induction (Turnbull et al. 2003). These results, coupled with ones made in the present study, strongly support our recent observations demonstrating a direct link between circulating IL-6 and brain COX-2 expression (Rummel et al. 2006). In those experiments we clearly demonstrated that IL-6 injection induces COX-2 expression in endothelial cells lining the microvasculature of the brain (Rummel et al. 2006) and that neutralization of LPS-induced circulating IL-6 almost totally abolishes the expression of this enzyme in the same structures. In addition to the changes in the levels of COX-2 in the current study, we have observed a significant reduction in the levels of mPGES-1 expression after TURP in late-pregnant animals. This enzyme is involved in the last step of PGE2 synthesis, downstream of COX-2, and is fundamental in TURP-induced fever (Saha et al. 2005). In the central nervous system, regulation of mPGES-1 expression has been shown to be linked with that of COX-2 after LPS challenge (Yamagata et al. 2001; Ivanov et al. 2002; Ivanov & Romanovsky, 2004). Our findings support the hypothesis of overlapping mechanisms of transcriptional regulation for both enzymes (Yamagata et al. 2001; Ivanov et al. 2002; Ivanov & Romanovsky, 2004), which is likely controlled by IL-6 in the case of TURP-induced inflammation. Traditionally, a central role in the regulation of COX-2 and mPGES-1 expression has been ascribed to IL-1β and other molecules classically involved in NF-κB activation (Laflamme et al. 1999; Kojima et al. 2004; Nadjar et al. 2005; Sooranna et al. 2006). The observations made in the current study do not negate this hypothesis since we have demonstrated that hypothalamic IL-1β is induced in both groups of TURP-treated animals but are reduced significantly in pregnant females 11 h after TURP injection (Fig. 6 The observation that pregnant animals responded to the TURP challenge with a significant induction of both hypothalamic COX-2 and mPGES-1 mRNAs (Figs 4A In previous reports, the inability to find altered molecular fever pathways in the central nervous system after LPS during late pregnancy, upstream of PGE2 synthesizing enzymes (Mouihate et al. 2005; Harre et al. 2006), could stem from the nature of the given stimulus. As mentioned earlier, LPS is capable of stimulating several organs to produce fever mediators that act in a highly redundant fashion, as is further evidenced by the lack of effect of targeted mutations (‘knock out’) of cytokines on LPS-febrile response (Kopf et al. 1994; Zheng et al. 1995; Kozak et al. 1997; Leon, 2002). Several of these mediators could activate similar intracellular signalling pathways, responsible for COX-2 induction, which could have masked our ability to detect alterations in such pathways. In contrast, in TURP-induced fever, the respective situation is such that elimination of any of the identified components in the cytokine pathway (TNFα, IL-1β and IL-6) abolishes this response (Zheng et al. 1995; Kozak et al. 1997; Luheshi et al. 1997; Leon, 2002) and this is readily reflected in the activation state of downstream mediators, as we report in the present study. Additionally, the use of different controls groups (NP females in the current study and GD 15 and lactating females in Mouihate et al. 2005 and Harre et al. 2006) could explain some of these inconsistencies. The mechanisms underlying the blunted IL-6 production during pregnancy were not directly addressed in our study; however, several interesting possibilities arise. TURP-induced fever depends largely on IL-6 induction and release into the circulation, as a direct result of localized release of other pyrogenic cytokines such as TNFα and IL-1β (Luheshi et al. 1997; Turnbull et al. 2003). Our previous demonstration that IL-1ra induction is enhanced after LPS injection in late-pregnant rats (Ashdown et al. 2006b), does not extend to all inflammation models such as the one used in the current study; however, it is still feasible that IL-1ra induction in the local site of inflammation (where subcutaneous adipose tissue may be activated) may be enhanced, thus indirectly preventing IL-6 synthesis by inhibiting the action of IL-1β at the level of the necrotic tissue. Other plausible candidates for the reduced IL-6 production during near-term pregnancy are progesterone and oestrogen, that act as generalized modulators of both innate and adaptive immunity (Beagley & Gockel, 2003; Doria et al. 2006). Oestrogen levels rise towards the end of pregnancy (from GD 17 onwards), while progesterone levels, that are maintained at a very high level throughout most of the duration of pregnancy, diminish around GD 19 (Mann & Bridges, 2001). Oestrogen has been shown to decrease the inflammatory effects of carrageenan (Cuzzocrea et al. 2001), IL-1β (Ospina et al. 2004) and LPS (Vegeto et al. 2001; Mouihate & Pittman, 2003). Its anti-inflammatory effect seems to stem from its ability to arrest NF-κB-mediated transcription (Ghisletti et al. 2005) of genomic targets that include IL-6 (Galien & Garcia, 1997) and COX-2 genes (Mouihate & Pittman, 2003; Ospina et al. 2004). This could account for the abolished effects of TURP in dams at GD 18 described in our study. Mouihate & Pittman (2003) showed that oestrogen and progesterone replacement reduced circulating IL-6 induction by IL-1β, but not after LPS injection, although fever and COX-2 expression were modulated in the opposite direction. However, the effect of different doses of oestrogen, in the presence of low levels of progesterone, has not been determined. The physiological significance of reduced fever or immune activation during pregnancy is generally regarded as a protective mechanism against the detrimental effects of an abnormal rise in core body temperature or cytokines on fetal development. This is based on a growing body of evidence suggesting that immune activation during mid- or late-pregnancy is a risk factor strongly associated with increased incidence of psychiatric disorders such as cerebral palsy, autism and schizophrenia (Boksa, 2004; Fortier et al. 2004; Meyer et al. 2005, 2006; Ashdown et al. 2006a). Accordingly, prenatal exposure to IL-6 was shown to induce abnormalities in hippocampal structure, deficits in spatial working memory, hypertension and alterations in stress response in the adult offspring (Samuelsson et al. 2004; Samuelsson et al. 2006). Based on these observations and the results from the current study, it would appear that this cytokine, which has been shown to cross the blood–placental barrier (Dahlgren et al. 2006), plays a significant role in the reported neurodevelopmental defects associated with maternal infection, stress or injury during gestation and could provide a promising pharmacological target to help meliorate these effects. Acknowledgments This work was supported by Canadian Institutes of Health Research and National Alliance for Research on Schizophrenia and Depression. A.A.V. is a recipient of a PhD scholarship from the Canadian Bureau of International Education. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Science. 1979 Jan 26; 203(4378):374-6.
[Science. 1979]Physiol Rev. 1991 Jan; 71(1):93-127.
[Physiol Rev. 1991]Clin Chim Acta. 2006 Sep; 371(1-2):13-24.
[Clin Chim Acta. 2006]J Appl Physiol. 2002 Jun; 92(6):2648-55.
[J Appl Physiol. 2002]Am J Physiol Regul Integr Comp Physiol. 2002 Nov; 283(5):R1104-17.
[Am J Physiol Regul Integr Comp Physiol. 2002]Am J Physiol Regul Integr Comp Physiol. 2005 Nov; 289(5):R1265-72.
[Am J Physiol Regul Integr Comp Physiol. 2005]J Neuroendocrinol. 2006 Jan; 18(1):57-63.
[J Neuroendocrinol. 2006]Am J Physiol Regul Integr Comp Physiol. 2006 Apr; 290(4):R871-80.
[Am J Physiol Regul Integr Comp Physiol. 2006]J Physiol. 2000 Aug 1; 526 Pt 3():653-61.
[J Physiol. 2000]Am J Physiol Regul Integr Comp Physiol. 2006 Nov; 291(5):R1316-26.
[Am J Physiol Regul Integr Comp Physiol. 2006]J Physiol. 2004 Nov 15; 561(Pt 1):263-72.
[J Physiol. 2004]Cytokine. 1999 Feb; 11(2):95-103.
[Cytokine. 1999]Am J Physiol Regul Integr Comp Physiol. 2006 Nov; 291(5):R1316-26.
[Am J Physiol Regul Integr Comp Physiol. 2006]J Appl Physiol. 2002 Aug; 93(2):531-6.
[J Appl Physiol. 2002]Exp Physiol. 2003 Nov; 88(6):747-54.
[Exp Physiol. 2003]J Physiol. 2000 Aug 1; 526 Pt 3():653-61.
[J Physiol. 2000]Am J Physiol Regul Integr Comp Physiol. 2006 Nov; 291(5):R1316-26.
[Am J Physiol Regul Integr Comp Physiol. 2006]Endocrinology. 2000 Oct; 141(10):3749-63.
[Endocrinology. 2000]Nat Immunol. 2003 Jun; 4(6):540-5.
[Nat Immunol. 2003]Am J Physiol Regul Integr Comp Physiol. 2007 Apr; 292(4):R1667-74.
[Am J Physiol Regul Integr Comp Physiol. 2007]Brain Res Bull. 2001 Mar 1; 54(4):443-53.
[Brain Res Bull. 2001]Ann N Y Acad Sci. 2006 Jun; 1069():444-53.
[Ann N Y Acad Sci. 2006]J Appl Physiol. 2002 Aug; 93(2):531-6.
[J Appl Physiol. 2002]Am J Physiol Regul Integr Comp Physiol. 2002 Dec; 283(6):R1346-53.
[Am J Physiol Regul Integr Comp Physiol. 2002]Am J Physiol Regul Integr Comp Physiol. 2002 Sep; 283(3):R800-5.
[Am J Physiol Regul Integr Comp Physiol. 2002]Endocrinology. 2003 May; 144(5):1894-906.
[Endocrinology. 2003]Am J Physiol Regul Integr Comp Physiol. 2006 Nov; 291(5):R1316-26.
[Am J Physiol Regul Integr Comp Physiol. 2006]Am J Physiol Regul Integr Comp Physiol. 2005 May; 288(5):R1100-7.
[Am J Physiol Regul Integr Comp Physiol. 2005]J Neurosci. 2001 Apr 15; 21(8):2669-77.
[J Neurosci. 2001]Am J Physiol Regul Integr Comp Physiol. 2002 Nov; 283(5):R1104-17.
[Am J Physiol Regul Integr Comp Physiol. 2002]Front Biosci. 2004 May 1; 9():1977-93.
[Front Biosci. 2004]J Neurosci. 1999 Dec 15; 19(24):10923-30.
[J Neurosci. 1999]Arthritis Res Ther. 2004; 6(4):R355-65.
[Arthritis Res Ther. 2004]J Cereb Blood Flow Metab. 2005 Aug; 25(8):1047-59.
[J Cereb Blood Flow Metab. 2005]Mol Hum Reprod. 2006 Oct; 12(10):625-31.
[Mol Hum Reprod. 2006]Am J Physiol Regul Integr Comp Physiol. 2002 Sep; 283(3):R800-5.
[Am J Physiol Regul Integr Comp Physiol. 2002]Am J Physiol Regul Integr Comp Physiol. 2003 Mar; 284(3):R860-1; author reply R861-5.
[Am J Physiol Regul Integr Comp Physiol. 2003]Am J Physiol Regul Integr Comp Physiol. 2005 Nov; 289(5):R1265-72.
[Am J Physiol Regul Integr Comp Physiol. 2005]J Neuroendocrinol. 2006 Jan; 18(1):57-63.
[J Neuroendocrinol. 2006]Nature. 1994 Mar 24; 368(6469):339-42.
[Nature. 1994]Immunity. 1995 Jul; 3(1):9-19.
[Immunity. 1995]J Appl Physiol. 2002 Jun; 92(6):2648-55.
[J Appl Physiol. 2002]Endocrinology. 2003 May; 144(5):1894-906.
[Endocrinology. 2003]Am J Physiol Regul Integr Comp Physiol. 2007 Apr; 292(4):R1667-74.
[Am J Physiol Regul Integr Comp Physiol. 2007]FEMS Immunol Med Microbiol. 2003 Aug 18; 38(1):13-22.
[FEMS Immunol Med Microbiol. 2003]Ann N Y Acad Sci. 2006 Jun; 1069():247-56.
[Ann N Y Acad Sci. 2006]Prog Brain Res. 2001; 133():251-62.
[Prog Brain Res. 2001]Brain Res Brain Res Rev. 2004 Apr; 45(1):1-17.
[Brain Res Brain Res Rev. 2004]J Psychiatr Res. 2004 May-Jun; 38(3):335-45.
[J Psychiatr Res. 2004]Neurosci Biobehav Rev. 2005; 29(6):913-47.
[Neurosci Biobehav Rev. 2005]J Neurosci. 2006 May 3; 26(18):4752-62.
[J Neurosci. 2006]Mol Psychiatry. 2006 Jan; 11(1):47-55.
[Mol Psychiatry. 2006]